Cardiac resynchronization therapy response in cardiac sarcoidosis.
cardiac resynchronization therapy
cardiac sarcoidosis
implantable cardioverter defibrillator
sarcoidosis
ventricular tachycardia
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
25
04
2022
received:
28
02
2022
accepted:
11
05
2022
pubmed:
24
7
2022
medline:
14
9
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
Cardiac sarcoidosis (CS) is a nonischemic cardiomyopathy (NICM) characterized by infiltration of noncaseating granulomas involving the heart with highly variable clinical manifestations that can include conduction abnormalities and systolic heart failure. Cardiac resynchronization therapy (CRT) has shown significant promise in NICM, though little is known about its efficacy in patients with CS. To determine if CRT improved cardiac remodeling in patients with CS. We retrospectively reviewed all patients with a clinical or histological diagnosis of CS who underwent CRT implantation at the Mayo Clinic enterprise from 2000 to 2021. Baseline characteristics, imaging parameters, heart failure hospitalizations and need for advanced therapies, and major adverse cardiac events (MACE) were assessed. Our cohort was comprised of 55 patients with 61.8% male and a mean age of 58.7 ± 10.9 years. Eighteen (32.7%) patients had definite CS, 21 (38.2%) had probable CS, while 16 (29.1%) had presumed CS, and 26 (47.3%) with extracardiac sarcoidosis. The majority underwent CRT-D implantation (n = 52, 94.5%) and 3 (5.5%) underwent CRT-P implantation with 67.3% of implanted devices being upgrades from prior pacemakers or implantable cardioverter defibrillators. At 6 months postimplantation there was no significant improvement in ejection fraction (34.8 ± 10.9% vs. 37.7 ± 14.2%, p = .331) or left ventricular end-diastolic diameter (58.5 ± 10.2 vs. 57.5 ± 8.1 mm, p = .236), though mild improvement in left ventricular end systolic diameter (49.1 ± 9.9 vs. 45.7± 9.9 mm, p < .0001). Within the first 6 months postimplantation, 5 (9.1%) patients sustained a heart failure hospitalization. At a mean follow-up of 4.1± 3.7 years, 14 (25.5%) patients experienced a heart failure hospitalization, 11 (20.0%) underwent cardiac transplantation, 1 (1.8%) underwent left ventricular assist device implantation and 7 (12.7%) patients died. Our findings suggest variable response to CRT in patients with CS with no overall improvement in ventricular function within 6 months and a substantial proportion of patients progressing to advanced heart failure therapies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2072-2080Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Birnie D, Ha AC, Gula LJ, Chakrabarti S, Beanlands RS, Nery P. Cardiac sarcoidosis. Clin Chest Med. 2015;36(4):657-668.
Okada DR, Bravo PE, Vita T, et al. Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol. 2018;25(4):1136-1146.
Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624-632.
Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88(9):1006-1010.
McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007;297(22):2502-2514.
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-2150.
Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-2395.
Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-1549.
Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007;115(2):204-212.
Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-1338.
Tang AS, Wells GA, Arnold M, et al. Resynchronization/defibrillation for ambulatory heart failure trial: rationale and trial design. Curr Opin Cardiol. 2009;24(1):1-8.
Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368(17):1585-1593.
Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305-1323.
Rosenbaum AN, Kolluri N, Elwazir MY, et al. Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease. Int J Cardiol. 2021;335:66-72.
Bleeker GB, Bax JJ, Fung JW, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol. 2006;97(2):260-263.
Pitzalis MV, Iacoviello M, Romito R, et al. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. J Am Coll Cardiol. 2005;45(1):65-69.
Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 suppl):VI17-VI23.
Yufu K, Kondo H, Shinohara T, et al. Outcome of patients with cardiac sarcoidosis who received cardiac resynchronization therapy: comparison with dilated cardiomyopathy patients. J Cardiovasc Electrophysiol. 2017;28(2):177-181.
Martens P, Nijst P, Verbrugge FH, Dupont M, Tang WHW, Mullens W. Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology. Heart Rhythm. 2018;15(1):130-136.
Sairaku A, Yoshida Y, Nakano Y, et al. Cardiac resynchronization therapy for patients with cardiac sarcoidosis. Europace. 2017;19(5):824-830.
Patel D, Trulock KM, Toro S, et al. Effect of cardiac resynchronization therapy on left ventricular remodeling in patients with cardiac sarcoidosis. Am J Cardiol. 2019;123(2):329-333.
Iwai K, Sekiguti M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11(1):26-31.
Yu CM, Abraham WT, Bax J, et al. Predictors of response to cardiac resynchronization therapy (PROSPECT)-study design. Am Heart J. 2005;149(4):600-605.
Okada DR, Smith J, Derakhshan A, et al. Ventricular arrhythmias in cardiac sarcoidosis. Circulation. 2018;138(12):1253-1264.
Stees CS, Khoo MS, Lowery CM, Sauer WH. Ventricular tachycardia storm successfully treated with immunosuppression and catheter ablation in a patient with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2011;22(2):210-213.
Koplan BA, Soejima K, Baughman K, Epstein LM, Stevenson WG. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm. 2006;3(8):924-929.
Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6(4):501-511.
McLeod CJ, Shen WK, Rea RF, et al. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy. Heart Rhythm. 2011;8(3):377-382.
Barsheshet A, Goldenberg I, Moss AJ, et al. Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. Eur Heart J. 2011;32(13):1622-1630.
Adelstein EC, Tanaka H, Soman P, et al. Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J. 2011;32(1):93-103.
Xu YZ, Cha YM, Feng D, et al. Impact of myocardial scarring on outcomes of cardiac resynchronization therapy: extent or location? J Nucl Med. 2012;53(1):47-54.
Nagai T, Nagano N, Sugano Y, et al. Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis. Circ J. 2015;79(7):1593-1600.
Biton Y, Kutyifa V, Cygankiewicz I, et al. Relation of QRS duration to clinical benefit of cardiac resynchronization therapy in mild heart failure patients without left bundle branch block: the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy substudy. Circ Heart Fail. 2016;9(2):e002667.
Peterson PN, Greiner MA, Qualls LG, et al. QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. JAMA. 2013;310(6):617-626.
Leong DP, Höke U, Delgado V, et al. Predictors of long-term benefit of cardiac resynchronization therapy in patients with right bundle branch block. Eur Heart J. 2012;33(15):1934-1941.
Forotan H, Rowe MK, Korczyk D, Kaye G. Cardiac sarcoidosis, left ventricular impairment and chronic right ventricular pacing: pacing or pathology? Heart Lung Circ. 2017;26(11):1175-1182.
Rickard J, Jackson G, Spragg DD, et al. QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm. 2012;9(10):1674-1678.
Rickard J, Cheng A, Spragg D, et al. QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. Heart Rhythm. 2013;10(1):55-60.
Jastrzebski M, Baranchuk A, Fijorek K, et al. Cardiac resynchronization therapy-induced acute shortening of QRS duration predicts long-term mortality only in patients with left bundle branch block. Europace. 2019;21(2):281-289.
Ma J, Liu Y, Dong Y, Chen M, Xia L, Xu M. Association between changes in QRS width and echocardiographic responses to cardiac resynchronization therapy: a systematic review and meta-analysis. Medicine. 2020;99(2):e18684.
Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31(2):372-379.